Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

Go back to Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
(NASDAQ: PRME) Delayed: 3.21 --0 (-0%)
Previous Close $3.21    52 Week High $21.72 
Open $3.21    52 Week Low $18.36 
Day High $3.21    P/E N/A 
Day Low $3.21    EPS $0.00 
Volume 340,309